Addiction

December 4, 2019

As life expectancy and fertility rates decline, health politics more key than ever

Ohio, Pennsylvania, Kentucky, and Indiana — if you’re obsessed with national politics, these states might register in your mind as key partisan battlegrounds. But if you’re focused on Americans’ health and well-being, these states — along with New Hampshire, Maine, Vermont, and West Virginia — may be causes for different and considerable concern: the nation’s plummeting life expectancy.

These states are flashing warning signs, racking up the greatest relative increases in death rates among young and middle-aged adults (New Hampshire, Maine, Vermont, West Virginia, and Ohio).

Excess deaths among Americans in their prime, that is individuals in the 25 to 64 age group who would live longer if mortality rates improved, also were highly concentrated geographically, with fully a third of them in just four states: Ohio, Pennsylvania, Kentucky and Indiana, experts say.

December 1, 2019

With new heat on THC and CBD use, will zeal for marijuana keep growing?

by Patrick A. Malone

Fans of marijuana and its related products may want to take careful note of developments regarding their health and safety effects.

Federal researchers are racing to trace thousands of cases of lung damage and dozens of deaths to so-called smokeless consumption of tetrahydrocannabinol or THC, the ingredient that produces the marijuana high. Other federal officials also are warning about cannabidiol or CBD — a derivative of marijuana or its cousin hemp — and its burgeoning and unapproved use in an array of products on the market.

To be sure, because blue-nose attitudes blocked rigorous research on marijuana and other drugs, medical scientists have been scrupulous in declining to make sweeping declarations about grass and its potential benefits or harms.

November 24, 2019

On vaping, gun violence, and health insurance, the big talk flows, but action, not so much

by Patrick A. Malone

When it comes to key health concerns of the American public, President Trump and his administration have offered evidence anew that whatever they say may not last to the next political moment, that inaction is its own powerful kind of action, and that what officials say they’re doing may be exactly the opposite.

This is not intended as partisan commentary. It reflects the turn of a few news cycles and how Trump and his officials have dealt with:

The outbreak of serious lung illnesses and deaths tied to vaping

November 1, 2019

Too many spoons full of sugar going down in kids’ drinks

by Patrick A. Malone

Grownups shouldn’t be surprised that child obesity is a major and rising concern for 1 in 5 of the nation’s young, putting their short- and long-term health at serious peril: That’s because Big Sugar and major food makers persist in a costly, relentless barrage on kids and adults for unhealthful products, notably sweet drinks that hook children into hard-to-break habits for a lifetime.

Although pediatricians and nutrition experts keep warning that babies and tots, especially, should get much lower amounts of sugar in various forms in their daily diet, almost “two-thirds of the $2.2 billion in beverages marketed to children contained added sweeteners, according to a report released last week by the Rudd Center for Food Policy & Obesity at the University of Connecticut,” the New York Times reported.

Rudd researchers found that just three food industry titans sprinkled $21 million in advertising for sugary liquids.

October 20, 2019

Billions from landmark opioids case? It’d be just a start in dealing with crisis

by Patrick A. Malone

Tens of billions of dollars. Those sound like hefty sums. But will it ever be enough? Will, say, $50 billion offer justice and appropriate recompense to a nation wracked by an opioid and overdose crisis?

These figures aren’t pulled from thin air. They’re part of the reported settlement under negotiations to resolve more than 2,300 lawsuits, all bundled up now and under the sway of a federal judge in Ohio. He will launch a landmark opioids’ trial this week, starting with claims by two Ohio counties, unless Big Pharma firms remaining as defendants and the plaintiffs — including states, counties, cities, and Indian tribes — can strike a deal and settle.

The claimants, of course, themselves represent huge and diverse interests: their millions of individual constituents. And they disagree on how much money is fair, how it should be divided, and more. The drug makers and distributors, having seen some of their peers bail already for significant sums, assert they have reached their negotiating ceiling, somewhere around that magic $50 billion.

October 8, 2019

FDA oversight looks shaky with drug recalls, rising vaping deaths and injuries

by Patrick A. Malone

Tens of millions of Americans may have been startled in recent days by the much-publicized pulling from the shelves of widely used drugs like ranitidine (aka Zantac), an over-the-counter heartburn remedy, and select lots of the prescription blood-pressure medications losartan, valsartan and irbesartan.

The actions occurred after cancer-causing chemicals known as nitrosamines — N-Nitroso-N-methyl-4-aminobutyric acid, or NMBA, and N-Nitrosodimethylamine, or NDMA— were detected in them.

September 22, 2019

It’s a season to get ripe view of money-grasping Big Pharma and plutocrats

by Patrick A. Malone

For those who get a rise out of following the plight of plundering plutocrats, forget about pop culture shows like Succession, Dynasty, or Empire. Instead, it may be worth peeking in on the true-life Sackler family saga. It also underscores the truth of this idea: Never get between Big Pharma and a buck.

The Sackler story, turning on the fate of the family’s Purdue pharmaceutical firm and a fortune estimated at $13 billion, has been ripe with recent developments, including a potential settlement of thousands of claims by states, counties, cities, Indian tribes, and others — all claiming billions of dollars in damages due to the maker’s aggressive and less than accurate sales and marketing of its prescription painkiller OxyContin.

With a federal judge in Ohio consolidating and pushing a “global resolution” of a giant number of opioid-related lawsuits, Purdue and the Sacklers announced a tentative settlement of many of the governments-filed claims. Roughly half the plaintiffs were eager to get what money they could — to not only help constituents staggered by damages due to opioids, overdoses, and addictions, but also to refill government coffers depleted by the huge costs of dealing with nightmares caused by the painkillers.

September 15, 2019

Trump administration now seeks to vaporize vaping, banning candy flavorings

by Patrick A. Malone

After standing to one side while vaping hooked a generation of young Americans on nicotine, the Trump Administration has now abruptly decided to try to vaporize youthful vaping by banning candy-like flavorings favored by e-cigarette users.

The president and Alex Azar, the chief of the Health and Human Services agency, announced the latest e-cigarette and vaping crackdown. It still must be defined in regulations, practices, and the financial support for the federal Food and Drug Administration to enforce it. FDA Commissioner Ned Sharpless and First Lady Melania Trump also participated in the Oval Office session.

The White House announcement came as public officials add daily to the toll of a sudden outbreak of reported deaths (at least a half dozen) and serious respiratory harms (hundreds of cases in three dozen or so states) blamed on vaping. Investigations continue as to the cause of the e-cigarette-related fatalities and injuries.

September 8, 2019

As deaths and lung damage cases rise, isn’t it clear that vaping is unhealthy?

by Patrick A. Malone

How well does Scott Gottlieb, the former federal Food and Drug Commissioner, sleep at night? Or does he even pause to think much about his role in opening the door to what has become a widening and lethal health menace: vaping and e-cigarettes?

The federal Centers for Disease Control and Prevention has joined with respected specialists in public health and lung disorders to urge the public, most especially young Americans, to stop vaping and using e-cigarettes at least until authorities can sort out an outbreak of serious problems connected with the trendy practices involving inhaling of substances catalyzed by electric devices.

Vaping suddenly has been implicated in 450 cases in 33 states and it has been tied to at least five deaths. Dozens of young people have been hospitalized, some with significant and sustained lung damage requiring extensive medical treatment.

September 1, 2019

Big Pharma flinches in opioids suits: a J&J loss in Okla. and a Sackler bid

by Patrick A. Malone

Big Pharma has hit at least two pain points of potential significance as government officials and trial lawyers work to hold drug makers accountable for at least some of the carnage caused by prescription painkillers.

There’s still a far way to go before companies see a full legal reckoning in the civil justice system for opioid overdose deaths that have killed an estimated 400,000 Americans since 2007, as well the drugs causing tens of thousands of cases of suffering and addiction.

But Oklahoma officials have struck hard at pharmaceutical interests by winning a $572-million nuisance ruling from a state judge against Johnson and Johnson, a legendary and once-respected health care brand.